Related Experiment Videos
New designs for phase 2 clinical trials.
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA. ehestey@mdanderson.org
Blood
|February 1, 2003
Summary
Conventional phase 2 clinical trials are inefficient. Randomized selection trials offer a more reliable and efficient method for comparing multiple therapies using diverse outcomes, improving drug development.
Area of Science:
- Clinical Trial Design
- Drug Development
- Biostatistics
Background:
- Conventional phase 2 clinical trials are typically single-arm, using a single binary outcome, which inadequately serves clinical investigators.
- Comparing separate single-arm trials confounds treatment effects with trial effects, making reliable treatment comparisons impossible.
- This methodology is inefficient and unreliable for selecting therapies for phase 3 investigation.
Purpose of the Study:
- To address the limitations of conventional phase 2 trial designs.
- To propose a new paradigm for phase 2 trials that are inherently comparative and utilize multiple outcomes.
- To improve the efficiency and reliability of selecting therapies for phase 3 clinical trials.
Main Methods:
- Development of a general paradigm for randomized selection trials.
- These trials evaluate multiple therapies simultaneously.
- Utilizes multiple outcome variables to capture complex clinical phenomena.
Main Results:
- Demonstrated that randomized selection trials can reliably estimate treatment effects.
- Showcased the ability to distinguish treatment effects from trial effects.
- Presented three illustrative applications of this novel trial approach.
Conclusions:
- Conventional single-arm phase 2 trials are unreliable for therapy selection.
- Randomized selection trials provide a more efficient and robust framework for phase 2 drug development.
- This approach optimizes the use of limited patient populations and resources in evaluating new therapies.